In 2 previous blogs we followed Andre' Singleton and his achieving remission from Hodgkin's.
He traveled to Washington, D.C., to volunteer in CureSearch’s national conference. He went to New Jersey to meet the three Newark doctors. While there he saw his story told in the local newspaper. He had his picture taken with Bill Cosby.
People took up a collection that night in New Jersey to support his treatment and his school plans. While at the bank the next morning, the curious bank teller got a glimpse of his story and read his news clips. She asked him to speak to her church’s youth group about cancer awareness. The kids were so responsive and asked so many questions, the teller, Ebony Williams, said. He made them think about it. They wanted to learn more. The trips, the radio shows, meeting Cosby — it’s all just phenomenal to Singleton’s mother, Ramona Jackson.
Life isn't all roses - see his blog for more info.
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...